6 past transactions

gyde

Seed Round in 2022
Gyde offers digital micro-learning and cross-company coaching for managers. Gyde builds a fully digital talent development solution that enables employees to learn through app-based microlearning and peer coaching sessions. They connect employees with peers from other companies to foster a steep learning curve through social learning.

Deep Care

Seed Round in 2022
Deep Care operates a health management platform focused on promoting healthy habits to help individuals achieve their personal wellness goals. The company offers a digital health coaching service that utilizes a plug-and-play desktop device equipped with a 3D sensor. This technology records users' posture and identifies unhealthy behaviors through artificial intelligence. By providing tailored instructions for exercises, ergonomic work practices, and essential reminders such as hydration, Deep Care aims to optimize health habits and enhance overall well-being. The platform is supplemented by extensive data insights developed in collaboration with Fraunhofer IOSB and FZI, ensuring a comprehensive approach to health management.

Uptempo

Series C in 2018
Uptempo is the software provider for effective Marketing Resource Management (MRM). The company gives enterprise marketers the visibility and control to optimize their marketing operations. The enterprise-level MRM solution turns marketing into a business-building powerhouse by letting marketing leaders get on top of their budgets, people workflows, campaigns, and marketplace performance. The company's all-in-one modular marketing suite covers the entire marketing process, including planning, budgeting, creation, development, and asset management, by analyzing content and providing performance reviews in a closed loop, allowing medium and large organizations to keep team members, suppliers, and partners aligned and marketing productivity to increase.

Uptempo

Series B in 2017
Uptempo is the software provider for effective Marketing Resource Management (MRM). The company gives enterprise marketers the visibility and control to optimize their marketing operations. The enterprise-level MRM solution turns marketing into a business-building powerhouse by letting marketing leaders get on top of their budgets, people workflows, campaigns, and marketplace performance. The company's all-in-one modular marketing suite covers the entire marketing process, including planning, budgeting, creation, development, and asset management, by analyzing content and providing performance reviews in a closed loop, allowing medium and large organizations to keep team members, suppliers, and partners aligned and marketing productivity to increase.

Amcure

Series B in 2016
amcure is a privately held, clinical-stage company developing peptide-based compounds for the treatment of highly metastatic forms of squamous cancer. Established in 2012, amcure GmbH is a spin-off from the Karlsruhe Institute of Technology (KIT) and is supported by a grant from the German Federal Ministry of Education and Research. amcure leverages its in-depth knowledge of CD44 target biology to develop a novel therapeutic approach to treat metastatic squamous tumors. In cancer, blocking the extracellular target CD44v6 has a beneficial effect on several relevant receptor tyrosine kinase pathways. Their first-in-class CD44v6-inhibitor AMC303 entered clinical development in solid tumors in Q4 2016.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.